Bioventus Inc. (BVS) vs MoonLake Immunotherapeutics (MLTX)
A side-by-side comparison of Bioventus Inc. and MoonLake Immunotherapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BVS
Bioventus Inc.
$13.23HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
MLTX
MoonLake Immunotherapeutics
$11.27HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Total return — BVS vs MLTX
growth of $100 · dividends reinvested · last 6yBVS -29.6% (-5.7%/yr)MLTX -1.1% (-0.2%/yr)MLTX compounded faster over this window
BVS MLTX
BVS vs MLTX: by the numbers
- •MLTX is the larger company ($948M vs $896M market cap).
- •BVS is profitable (9.36% net margin) while MLTX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | BVS | MLTX |
|---|---|---|
| P/E ratio | 17.18 | N/A |
| Forward P/E | 16.99 | N/A |
| P/S ratio | 1.54 | N/A |
| P/B ratio | 3.93 | 2.21 |
| EV / EBITDA | 10.56 | N/A |
| FCF yield | 10.52% | N/A |
Profitability
| Metric | BVS | MLTX |
|---|---|---|
| Gross margin | 68.00% | 0.00% |
| Operating margin | 10.63% | 0.00% |
| Net margin | 9.36% | 0.00% |
| ROE | 23.86% | -61.58% |
| ROIC | 11.37% | -50.77% |
Growth (annualized)
| Metric | BVS | MLTX |
|---|---|---|
| Revenue CAGR (5Y) | 11.82% | N/A |
| EPS CAGR (5Y) | -5.03% | N/A |
| FCF CAGR (5Y) | 43.36% | N/A |
| Total return CAGR (5Y) | -0.81% | 2.81% |
Frequently asked
- Is BVS or MLTX more profitable?
- BVS runs the higher net margin — BVS at 9.36% versus MLTX at 0.00%.
- How have BVS and MLTX total returns compared?
- Over the past 5 years, BVS delivered -0.81% and MLTX delivered 2.81% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bioventus P/E ratioBioventus ROEMoonLake Immunotherapeutics ROEBioventus operating marginMoonLake Immunotherapeutics operating marginBioventus revenue growthMoonLake Immunotherapeutics revenue growthBioventus free cash flowMoonLake Immunotherapeutics free cash flow
Bioventus & MoonLake Immunotherapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.